Kenvue narrowly missed Wall Street estimates for second-quarter results as inflation, tariffs and currency-related costs squeezed margins. Kenvue's adjusted gross margin fell to 60.2% from 60.9% a year earlier, as inflation, tariffs and currency-related costs outweighed some of the benefits from supply-chain savings and higher prices. Quarterly sales rose 3% to $3.96 billion, but slightly missed analysts' estimate of $3.97 billion. ADVERTISEMENTDivisional PerformanceSelf care sales rose 2.2% to $1.59 billion on improved Tylenol performance in the US, while Zyrtec and Pepcid gained market share. Skin health and beauty sales rose 5.1% to $1.11 billion, driven by higher sales of hair- and face-care products, including OGX and Neutrogena.